Latest From KemPharm Inc.
The latest drug development news and highlights from the Pink Sheet FDA Performance Tracker.
Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.
Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.
Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.
- Drug Discovery Tools
- Controlled Release
- Drug Delivery
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- KemPharm Inc.
- Senior Management
Travis C Mickle, PhD, Pres., CEO & Chmn.
R. LaDuane Clifton, CFO, Secretary & Treasurer
Christopher Lauderback, PhD, VP, Manufacturing
Sven Guenther, PhD, EVP, R&D
Gordon "Rusty" K Johnson, CBO
Rene A Braeckman, PhD, VP, Clinical Dev.
- Contact Info
Phone: (319) 665-2575
1180 Celebration Blvd.
Celebration, FL 34747
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.